CORTEF (hydrocortisone) by Pfizer is corticosteroid hormone receptor agonists [moa]. First approved in 1952.
Drug data last refreshed 31m ago · AI intelligence enriched 1w ago
CORTEF (hydrocortisone) is an oral corticosteroid tablet that acts as a hormone receptor agonist, mimicking the body's natural cortisol to reduce inflammation and suppress immune responses. It is used across multiple indications including adrenal insufficiency, inflammatory conditions, and various allergic/autoimmune disorders. The drug works by binding to glucocorticoid receptors to produce anti-inflammatory and immunosuppressive effects.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely in defensive/maintenance mode with stable but modest headcount.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
Worked on CORTEF at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CORTEF offers stability in a mature, well-understood market but limited growth upside given the approaching loss of exclusivity and minimal clinical innovation. Roles focus on defending market share against generics, managing pricing/access, and optimizing existing formulations rather than driving new pipeline value.